Bimekizumab efficacy for moderate to severe plaque psoriasis across patient subgroups: Pooled results from 3 multicenter, randomized, double-blinded phase 3 trials

被引：0

作者：

Strober, Bruce ^{[1
,2
]}

Warren, Richard B. ^{[3
]}

Foley, Peter ^{[4
]}

Gooderham, Melinda ^{[5
,6
]}

Thaci, Diamant ^{[7
]}

Cullen, Eva ^{[8
]}

Cioffi, Christopher ^{[9
]}

Peterson, Luke ^{[9
]}

Madden, Cynthia ^{[9
]}

Armstrong, April ^{[10
]}

机构：

[1] Yale Univ, New Haven, CT 06520 USA

[2] Cent Connecticut Dermatol Res, Cromwell, CT USA

[3] Univ Manchester, Manchester NIHR Biomed Res Ctr, Dermatol Ctr, Salford Royal NHS Fdn Trust, Manchester, Lancs, England

[4] Univ Melbourne, St Vincents Hosp Melbourne, Fitzroy & Prob Med Res Inc, Skin Hlth Inst, Carlton, Vic, Australia

[5] Queens Univ, Skin Ctr Dermatol, Prob Med Res Peterborough, Kingston, ON, Canada

[6] Queens Univ, Kingston, ON, Canada

[7] Univ Lubeck, Inst & Comprehens Ctr Inflammat Med, Lubeck, Germany

[8] UCB Pharma, Brussels, Belgium

[9] UCB Pharma, Raleigh, NC USA

[10] USC, Keck Sch Med, Dermatol, Los Angeles, CA USA

来源：

关键词：

D O I：

暂无

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

25934

引用

页码：AB76 / AB76

页数：1